Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Lifted by Entropy Technologies LP

Entropy Technologies LP lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,700 shares of the life sciences company’s stock after acquiring an additional 2,137 shares during the quarter. Entropy Technologies LP’s holdings in Illumina were worth $1,697,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Empowered Funds LLC boosted its position in shares of Illumina by 9.7% in the 4th quarter. Empowered Funds LLC now owns 4,344 shares of the life sciences company’s stock valued at $580,000 after purchasing an additional 384 shares during the period. Golden State Wealth Management LLC purchased a new stake in Illumina during the fourth quarter valued at about $32,000. Lecap Asset Management Ltd. acquired a new position in shares of Illumina in the fourth quarter worth about $2,846,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Illumina by 116.9% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock worth $115,663,000 after acquiring an additional 466,519 shares in the last quarter. Finally, Strategic Financial Concepts LLC acquired a new stake in shares of Illumina during the fourth quarter valued at approximately $1,464,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 9.6 %

Shares of ILMN stock opened at $111.06 on Monday. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a market cap of $17.61 billion, a PE ratio of -14.46 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business’s 50 day moving average is $136.70 and its two-hundred day moving average is $135.43.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Equities analysts predict that Illumina, Inc. will post 4.42 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Morgan Stanley dropped their price target on Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. UBS Group upped their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada decreased their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a report on Friday. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus price target of $161.40.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.